Filing Flows › Adaptive Biotechnologies (ADPT) › Q3 2026 › vs Q3 2025
Adaptive Biotechnologies (ADPT) Q3 2026 vs Q3 2025 (year over year)
Adaptive Biotechnologies's revenue fell $10.1M (-11%) from $94.0M in Q3 2025 to $83.9M in Q3 2026.
Adaptive Biotechnologies, Q3 2026: revenue $83.9M (-11% year over year), operating margin -0.5%, net earnings $2.8M, operating cash flow $9.6M. The chart draws each line against Q3 2025, the increases inside each band.
Margins
| Q3 2026 | Q3 2025 | Change | |
|---|---|---|---|
| Free cash flow margin | 9.1% | -8.0% | +17.2 pts |
Every line
| Line | Q3 2026 | Q3 2025 | Change | % |
|---|---|---|---|---|
| Revenue | $83.9M | $94.0M | −$10.1M | -11% |
| Other income, net | $3.3M | −$745K | $4.0M | — |
| Costs & expenses | $87.2M | $94.0M | −$6.8M | -7% |
| Operating costs | $84.4M | $83.7M | $676K | +0.8% |
| Net earnings | $2.8M | $9.5M | −$6.7M | -71% |
| Cost of revenue | $19.9M | $18.2M | $1.8M | +10% |
| Research & development | $18.6M | $23.7M | −$5.0M | -21% |
| Sales & marketing | $26.9M | $23.5M | $3.4M | +15% |
| General & admin | $18.5M | $18.0M | $505K | +3% |
| Other operating costs | $428K | $428K | $0 | 0% |
| Operating cash sources | $16.8M | $26.8M | −$10.0M | -37% |
| Depreciation & amortization | $3.6M | $4.0M | −$366K | -9% |
| Share-based compensation | $10.4M | $13.3M | −$2.9M | -22% |
| Working capital & other | $7.2M | $33.9M | −$26.7M | -79% |
| Operating cash flow | $9.6M | −$7.1M | $16.7M | — |
| Free cash flow (OCF − capex) | $7.7M | −$7.5M | $15.2M | — |
| Capital expenditures | $1.9M | $409K | $1.5M | +372% |
Questions
How much did Adaptive Biotechnologies's revenue grow year over year in Q3 2026?
Adaptive Biotechnologies's revenue fell $10.1M (-11%) from $94.0M in Q3 2025 to $83.9M in Q3 2026.